Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.

Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, Borel Rinkes IHM, Molenaar IQ, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Eur J Surg Oncol. 2019 Sep;45(9):1674-1683. doi: 10.1016/j.ejso.2019.04.007. Epub 2019 Apr 11.

PMID:
31023560
2.

Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.

Barenboim A, Lahat G, Geva R, Nachmany I, Nakache R, Goykhman Y, Brazowski E, Rosen G, Isakov O, Wolf I, Klausner JM, Lubezky N.

Eur J Surg Oncol. 2018 Oct;44(10):1619-1623. doi: 10.1016/j.ejso.2018.07.057. Epub 2018 Aug 2.

PMID:
30146251
3.

Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.

Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R.

J Gastrointest Oncol. 2016 Aug;7(4):547-55. doi: 10.21037/jgo.2016.03.15.

4.

Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.

Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R.

Acta Oncol. 2015 Jul;54(7):979-85. doi: 10.3109/0284186X.2015.1004367. Epub 2015 Mar 3.

PMID:
25734581
5.

Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.

Hashemi-Sadraei N, Gbolahan OB, Salfity H, O'Neil B, House MG, Shahda S.

Am J Clin Oncol. 2018 Oct;41(10):982-985. doi: 10.1097/COC.0000000000000409.

PMID:
28968257
6.

Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.

Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE.

Acta Oncol. 2017 Mar;56(3):391-397. doi: 10.1080/0284186X.2016.1256497. Epub 2016 Nov 25.

PMID:
27885876
7.

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T, Kobayashi T, Mitsunaga S, Nakachi K, Ikeda M.

J Hepatobiliary Pancreat Sci. 2011 Jul;18(4):567-74. doi: 10.1007/s00534-011-0371-z.

PMID:
21331805
8.

Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.

Lewis S, Sastri SC, Arya S, Mehta S, Patil P, Shrivastava S, Phurailatpam R, Shrikhande SV, Engineer R.

J Gastrointest Oncol. 2019 Jun;10(3):474-482. doi: 10.21037/jgo.2019.01.25.

9.

Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.

Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersvärd R, Arnelo U, Del Chiaro M.

Ann Surg. 2019 Apr 2. doi: 10.1097/SLA.0000000000003301. [Epub ahead of print]

PMID:
30946073
10.

Induction Therapy in Localized Pancreatic Cancer.

Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF.

Pancreas. 2019 Aug;48(7):913-919. doi: 10.1097/MPA.0000000000001353.

PMID:
31268982
11.

Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.

Masui T, Doi R, Kawaguchi Y, Sato A, Nakano K, Ito T, Anazawa T, Takaori K, Uemoto S.

Surg Today. 2016 Nov;46(11):1282-9. doi: 10.1007/s00595-016-1310-z. Epub 2016 Feb 9.

PMID:
26860274
12.

Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):516-22. doi: 10.1016/j.ijrobp.2013.02.022. Epub 2013 Apr 5.

PMID:
23562768
13.

Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.

Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):837-44. doi: 10.1016/j.ijrobp.2013.12.030.

14.

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis.

Yoo C, Shin SH, Kim KP, Jeong JH, Chang HM, Kang JH, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Hwang DW, Song KB, Lee JH, Ryoo BY, Kim SC.

Cancers (Basel). 2019 Feb 26;11(3). pii: E278. doi: 10.3390/cancers11030278.

15.

Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.

Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, Strobel O, Neoptolemos JP, Mihaljevic AL, Büchler MW, Hackert T.

Ann Surg. 2019 Mar 20. doi: 10.1097/SLA.0000000000003270. [Epub ahead of print]

PMID:
30921051
16.

Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer.

Cho IR, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Hwang HK, Kang CM, Lee WJ, Park JY.

Pancreatology. 2013 Sep-Oct;13(5):539-43. doi: 10.1016/j.pan.2013.07.064. Epub 2013 Jul 18.

PMID:
24075521
17.

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer.

Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, Kim JR, Kim H, Kwon W, Kim SW.

Ann Surg Treat Res. 2017 Oct;93(4):186-194. doi: 10.4174/astr.2017.93.4.186. Epub 2017 Sep 28.

18.

Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.

Chapman BC, Gleisner A, Rigg D, Meguid C, Goodman K, Brauer B, Gajdos C, Schulick RD, Edil BH, McCarter MD.

J Surg Oncol. 2018 Apr;117(5):1073-1083. doi: 10.1002/jso.25004. Epub 2018 Feb 15.

PMID:
29448308
19.

Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, Weiss MJ, Zheng L, Wolfgang CL, He J.

Ann Surg. 2018 May;267(5):936-945. doi: 10.1097/SLA.0000000000002234.

PMID:
28338509
20.

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.

Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF.

Oncologist. 2016 Feb;21(2):178-87. doi: 10.1634/theoncologist.2015-0316. Epub 2016 Feb 1. Review.

Supplemental Content

Support Center